Clinical Trial Update: A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update for Prulacabtagene Leucel (Prula-cel) in autoimmune diseases, with enrollment by invitation ongoing across indications including Lupus neph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathies
• Lupus Nephritis
• Stiff-person Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Prulacabtagene Leucel (Prula-cel) (Prulacabtagene Leucel)

Snippet

Sponsor: Adicet Therapeutics | Conditions: Lupus Nephritis, Autoimmune Diseases | Phase 1 | Status: ENROLLING_BY_INVITATION